Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

Also called NCT06917664

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06917664
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06917664. Randomized; single masking; primary purpose treatment. Start 2025-06-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Condition
Ischemic Mitral Regurgitation
Condition
Angiotensin Receptor/Neprilysin Inhibitor
Intervention (Drug)
sacubitril/valsartan
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Chinese Academy of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct06917664
Content hash
6fc329e24954951a45ac025656bbb76d39dd6851aa81b935fd7ffdd34cbe331e